JP2024510975A5 - - Google Patents
Info
- Publication number
- JP2024510975A5 JP2024510975A5 JP2023555527A JP2023555527A JP2024510975A5 JP 2024510975 A5 JP2024510975 A5 JP 2024510975A5 JP 2023555527 A JP2023555527 A JP 2023555527A JP 2023555527 A JP2023555527 A JP 2023555527A JP 2024510975 A5 JP2024510975 A5 JP 2024510975A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- prostate cancer
- approximately
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160319P | 2021-03-12 | 2021-03-12 | |
| US63/160,319 | 2021-03-12 | ||
| PCT/US2022/019662 WO2022192481A1 (en) | 2021-03-12 | 2022-03-10 | Methods of treating prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510975A JP2024510975A (ja) | 2024-03-12 |
| JP2024510975A5 true JP2024510975A5 (cg-RX-API-DMAC7.html) | 2025-03-18 |
Family
ID=80952117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555527A Pending JP2024510975A (ja) | 2021-03-12 | 2022-03-10 | 前立腺癌を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12016847B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4304589B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024510975A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230156107A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117241797A (cg-RX-API-DMAC7.html) |
| ES (1) | ES3076129T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022192481A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR073923A1 (es) | 2008-10-31 | 2010-12-09 | Medivation Technologies Inc | Pirido( 4,3-b) indoles que contienen restos rigidos |
| CN102257076B (zh) | 2008-12-18 | 2014-07-30 | 纳幕尔杜邦公司 | 具有新颜料的粉末涂料组合物 |
| US8580399B2 (en) | 2011-04-08 | 2013-11-12 | Universal Display Corporation | Substituted oligoazacarbazoles for light emitting diodes |
| KR20140068883A (ko) | 2011-09-28 | 2014-06-09 | 이데미쓰 고산 가부시키가이샤 | 유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자 |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2961747B1 (en) | 2013-02-27 | 2017-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| US9458156B2 (en) * | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EA201990240A1 (ru) * | 2013-12-24 | 2019-06-28 | Бристол-Маерс Сквибб Компани | Новые трициклические соединения в качестве противораковых средств |
| US9580430B2 (en) * | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| RU2745999C1 (ru) * | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| US20190134004A1 (en) * | 2016-06-16 | 2019-05-09 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| CN111356695B (zh) * | 2017-10-27 | 2022-12-30 | 北京加科思新药研发有限公司 | 新的三环化合物 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
-
2022
- 2022-03-07 US US17/653,717 patent/US12016847B2/en active Active
- 2022-03-10 CN CN202280032513.3A patent/CN117241797A/zh active Pending
- 2022-03-10 KR KR1020237034510A patent/KR20230156107A/ko active Pending
- 2022-03-10 WO PCT/US2022/019662 patent/WO2022192481A1/en not_active Ceased
- 2022-03-10 JP JP2023555527A patent/JP2024510975A/ja active Pending
- 2022-03-10 EP EP22713194.3A patent/EP4304589B1/en active Active
- 2022-03-10 ES ES22713194T patent/ES3076129T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022340500A1 (en) | Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma | |
| JP2020519295A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| JP2022542238A5 (cg-RX-API-DMAC7.html) | ||
| FI2547205T3 (fi) | Uusia menetelmiä syövän kantasolujen kohdentamiseksi | |
| JP2022506062A5 (cg-RX-API-DMAC7.html) | ||
| RU2018137037A (ru) | Антинеопластические комбинации, содержащие hki-272 и винорелбин | |
| JP2009215293A5 (cg-RX-API-DMAC7.html) | ||
| JP2023522716A5 (cg-RX-API-DMAC7.html) | ||
| JP2022501383A5 (cg-RX-API-DMAC7.html) | ||
| Jiang et al. | Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts | |
| JP2025061087A (ja) | 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法 | |
| US20200397739A1 (en) | Synergistic composition of vitamin c and vitamin k1, and compositions thereof for the treatment of cancer | |
| JP2016502540A5 (cg-RX-API-DMAC7.html) | ||
| JP2016522188A5 (cg-RX-API-DMAC7.html) | ||
| JP6433686B2 (ja) | 癌治療用組成物の調製のためのイカリチンの使用 | |
| WO2022207648A1 (en) | A pi3k-delta inhibitor for the treatment of pancreatic cancer | |
| JP2023550740A5 (cg-RX-API-DMAC7.html) | ||
| CN101757623B (zh) | 一种5-ht受体激动剂固体药物组合物 | |
| CN104411309B (zh) | 阿可拉定在制备用于治疗原发性肝癌的药物中的用途 | |
| JP2023549522A5 (cg-RX-API-DMAC7.html) | ||
| CN102370639A (zh) | 一种萘普生和舒马普坦的复方制剂 | |
| JP7174370B2 (ja) | 予後改善剤 | |
| Pramanik et al. | Neutropenia due to palbociclib: A word of caution? | |
| CN101155600A (zh) | 放射线治疗增强剂 |